Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations

17 Jul 2019

Abstract excerpt

Papillary craniopharyngiomas (PCPs) are characterized by the presence of BRAF V600E mutations, which are emerging as a useful guide for diagnosis and treatment decision making. The ongoing multicenter phase 2 Alliance A071601 trial is evaluating the efficacy of BRAF and mitogen‐activated protein kinase kinase (MEK) inhibitors for patients with PCPs. With continued successful responses, it is proposed that BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Neurofibromatosis and Schwannoma Cases
Share to Pituitary Gland Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31314136
DOI: 10.1002/cncr.32197

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutationsPMID 31314136Read ↗

BRAF plus MEK inhibition effective in papillary craniopharyngioma.Semantic proximity Read ↗

Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.Semantic proximity Read ↗

Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature.Semantic proximity Read ↗

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.Semantic proximity Read ↗

Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the RAPID Consortium.Semantic proximity Read ↗

BRAF-MEK Inhibition Is Effective in BRAFV600E-Mutant Papillary Craniopharyngioma.Semantic proximity Read ↗

ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngiomaSemantic proximity Read ↗

Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review.Semantic proximity Read ↗

Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma.Semantic proximity Read ↗

Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.Semantic proximity Read ↗

Study protocol for preoperative classification using integrated screening and short-course neoadjuvant BRAF/MEK inhibition in newly diagnosed papillary craniopharyngioma (the PRECISE-PCP study): a prospective single-arm studySemantic proximity Read ↗

[Molecularly Targeted Therapy for Craniopharyngioma].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.